Novel Ciprofloxacin-Resistant, Nalidixic Acid-Susceptible Mutant of Staphylococcus aureus

Laura Piddock; YF Jin; Mark Webber; MJ Everett

doi:10.1128/AAC.46.7.2276-2278.2002

Novel Ciprofloxacin-Resistant, Nalidixic Acid-Susceptible Mutant of Staphylococcus aureus

Laura Piddock
, YF Jin
, Mark Webber
, MJ Everett

Immunology and Immunotherapy

Research output: Contribution to journal › Article

20 Citations (Scopus)

Abstract

A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.

Original language	English
Pages (from-to)	2276-2278
Number of pages	3
Journal	Antimicrobial Agents and Chemotherapy
Volume	46
Issue number	7
DOIs	https://doi.org/10.1128/AAC.46.7.2276-2278.2002
Publication status	Published - 1 Jul 2002

Access to Document

10.1128/AAC.46.7.2276-2278.2002

Cite this

@article{cf4df17300c648a0a581ada470e7f8c6,

title = "Novel Ciprofloxacin-Resistant, Nalidixic Acid-Susceptible Mutant of Staphylococcus aureus",

abstract = "A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.",

author = "Laura Piddock and YF Jin and Mark Webber and MJ Everett",

year = "2002",

month = jul,

day = "1",

doi = "10.1128/AAC.46.7.2276-2278.2002",

language = "English",

volume = "46",

pages = "2276--2278",

journal = "Antimicrobial Agents and Chemotherapy",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - Novel Ciprofloxacin-Resistant, Nalidixic Acid-Susceptible Mutant of Staphylococcus aureus

AU - Piddock, Laura

AU - Jin, YF

AU - Webber, Mark

AU - Everett, MJ

PY - 2002/7/1

Y1 - 2002/7/1

N2 - A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.

AB - A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.

UR - https://www.scopus.com/pages/publications/0035984816

U2 - 10.1128/AAC.46.7.2276-2278.2002

DO - 10.1128/AAC.46.7.2276-2278.2002

M3 - Article

C2 - 12069989

VL - 46

SP - 2276

EP - 2278

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 7

ER -

Novel Ciprofloxacin-Resistant, Nalidixic Acid-Susceptible Mutant of Staphylococcus aureus

Abstract

Access to Document

Fingerprint

Cite this